Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE
Pfizer Limited
10
Oral Suspension
2004-10-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT GEODON 10 mg/ml oral suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains ziprasidone hydrochloride monohydrate equivalent to 10 mg of ziprasidone. Excipients: Each ml contains 1.36 mg methyl parahydroxybenzoate. Each ml contains 0.17 mg propyl parahydroxybenzoate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension White to slightly yellow opaque cherry flavoured aqueous suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ziprasidone is indicated for the treatment of schizophrenia in adults. Ziprasidone is indicated for the treatment of manic or mixed episodes of moderate severity in bipolar disorder in adults, children and adolescents aged 10-17 years(prevention of episodes of bipolar disorder has not been established - _see_ _section 5.1)._ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ The recommended dose, in acute treatment of schizophrenia and bipolar mania, is 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment. It is of particular importance not to exceed the maximum dose as the safety profile above 160 mg/day has not been confirmed and ziprasidone is associated with dose-related prolongation of the QT interval _(see sections 4.3 and 4.4)._ In maintenance treatment of schizophrenia patients, ziprasidone should be administered at the lowest effective dose; in many cases, a dose of 20 mg twice daily may be sufficient. Measure the dose as closely as possible using the oral syringe provided. Ziprasidone oral suspension should be administered dir Read the complete document